# AbbVie

美国免疫学制药巨头——修美乐（2012–2023年全球最畅销生物制品）及下一代Skyrizi/Rinvoq；生物制品大型CDMO客户；NYSE: ABBV。

Source: https://cn.bioecon.ru/companies/abbvie/
Updated: 2026-06-19

- 国家: United States
- 营收: $56.3B
- 员工: ~50,000 emp

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 承诺十年内在美国研发与制造资本投资$1000亿；自2025年8月起已宣布美国制造业投资$22亿 | https://news.abbvie.com/2026-02-23-AbbVie-to-Invest-380-Million-in-North-Chicago-to-Further-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-United-States, https://www.abbvie.com/content/dam/abbvie-com2/pdfs/manufacture/abbvie-illinois-impact-fact-sheet.pdf, https://www.abbvie.com/manufacturing-investments.html, https://www.prnewswire.com/news-releases/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-302750567.html |
| 产能 | 通过在伊利诺伊州、北卡罗来纳州、马萨诸塞州及亚利桑那州投资新建多处设施，扩大本土生物制品、原料药及小容量注射剂（SVP）制剂产能 | https://news.abbvie.com/2026-02-23-AbbVie-to-Invest-380-Million-in-North-Chicago-to-Further-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-United-States, https://www.abbvie.com/manufacturing-investments.html, https://www.prnewswire.com/news-releases/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-302750567.html |
| 认证 | 100%的医疗器械生产基地通过ISO 13485认证；各基地还在推进ISO 14001、ISO 45001与ISO 50001认证 | https://www.abbvie.com/content/dam/abbvie-com2/pdfs/2025-esg-disclosure-supplement.pdf |
| 监管批准 | Skyrizi、Rinvoq、Vraylar、Ubrelvy、Qulipta及Vyalev等产品持续获得FDA与EMA批准；近期批准包括帕金森病疗法及c-Met高表达非小细胞肺癌治疗 | https://investors.abbvie.com/static-files/c3b8b9e2-9d03-4d72-ad4b-2ae4ac0dedfc, https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj, https://www.syneticx.com/blog/abbvie.html |
| 生产基地 | 生产基地位于美国（含伊利诺伊州、北卡罗来纳州、亚利桑那州、马萨诸塞州）及海外（德国、爱尔兰、意大利、法国、波多黎各、哥斯达黎加、新加坡） | https://news.abbvie.com/2026-02-23-AbbVie-to-Invest-380-Million-in-North-Chicago-to-Further-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-United-States, https://www.abbvie.com/manufacturing-investments.html, https://www.abbviecontractmfg.com/resources/pharma-manufacturing-plant-capability-matrix.html, https://www.pharmamanufacturing.com/all-articles/article/55286102/abbvie-plans-10b-investment-in-us-manufacturing-over-the-next-decade, https://www.prnewswire.com/news-releases/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-302750567.html |
| 员工人数 | 全球约57,000名员工；美国约29,000名员工，其中美国制造园区6,000余名 | https://investors.abbvie.com/static-files/c3b8b9e2-9d03-4d72-ad4b-2ae4ac0dedfc, https://news.abbvie.com/2026-02-23-AbbVie-to-Invest-380-Million-in-North-Chicago-to-Further-Expand-Active-Pharmaceutical-Ingredient-Manufacturing-in-the-United-States, https://www.abbvie.com/content/dam/abbvie-com2/pdfs/manufacture/abbvie-illinois-impact-fact-sheet.pdf, https://www.abbvie.com/manufacturing-investments.html, https://www.prnewswire.com/news-releases/abbvie-selects-north-carolina-for-new-1-4-billion-manufacturing-campus-302750567.html |
| 营收 | 2025年总销售额$611亿；2026年第二季度总收入$169.9亿 | https://pulse2.com/abbvie-skyrizi-and-rinvoq-generate-8-03-billion-as-humira-revenue-falls-36/, https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj |

独立来源: fiercepharma.com, pharmamanufacturing.com, prnewswire.com, pulse2.com, syneticx.com

## 技术

- [双特异性与多特异性抗体](https://cn.bioecon.ru/technology/bispecific-antibodies/)
- [生物合成透明质酸](https://cn.bioecon.ru/technology/biosynthetic-hyaluronic-acid/)
- [生物药 (Biologics)](https://cn.bioecon.ru/technology/biologics/)
- [重组肉毒毒素（生物合成 Botox）](https://cn.bioecon.ru/technology/recombinant-botulinum-toxin/)